The DASAPHARM team possesses extensive expertise in Business Development, Marketing, and Sales acquired through working with leading international pharmaceutical companies.

Our deep understanding of the Russian business culture plays a crucial role in bridging organizational and cultural gaps between end-customers and API suppliers. This comprehensive knowledge enables seamless execution of all aspects of your business.

DASAPHARM's successful track record in API commercialization in Russia includes a range of APIs such as Desmopressin, Tacrolimus, Rosuvastatin, Clopidogrel, Dorsolamide, Bicalutamide, Galantamine, Salbutamol, Bromocriptine, Memantine, Dorsolamide, Tropicamide, Trimetazidine, Omeprazol Pellets, Pharmaceutical Lactose and more.

We consistently monitor the pharmaceutical industry to stay up to date with the latest trends and developments in the Russian market.
As a proactive company, DASAPHARM focuses on developing our end-clients' product portfolios, assessing their R&D and production capabilities. Our tailored proposals are based on thorough market analysis utilizing import/export databases and registries.
With an extensive network of established relationships within end-client organizations, we facilitate project execution and remove any obstacles for our clients.
Working with us is characterized by smoothness, efficiency, and cost-effectiveness. We have a proven track record of overcoming deadlocks, barriers, and challenges between API manufacturers and end-clients at any stage of the business process, including Sourcing, R&D, Registration, and Commercialization.